Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Declines By 28.6%

180 Life Sciences Corp. (NASDAQ:ATNF) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 64,800 shares, a decline of 28.6% from the November 15th total of 90,800 shares. Currently, 13.2% of the company’s stock are sold short. Based on an average daily trading volume, of 1,960,000 shares, the short-interest ratio is presently 0.0 days.

180 Life Sciences Stock Up 2.7 %

NASDAQ ATNF traded up $0.05 during midday trading on Friday, hitting $1.93. 46,551 shares of the company traded hands, compared to its average volume of 746,371. 180 Life Sciences has a 52 week low of $1.16 and a 52 week high of $17.75. The company’s 50-day simple moving average is $2.83 and its 200-day simple moving average is $2.19.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.